American Society of Hematology

Figure 1

$Conditioning regimen and inoculum. (A) Twenty-five patients (September 2008-October 2009): 8 Gy in a single fraction at a fast dose rate with lung shielding on day –10, thiotepa (4 mg/kg per day) on days –10 and −9, fludarabine (40 mg/m2 per day) from days –10 to –6, and cyclophosphamide (35 mg/kg per day) on days –7 and –6. (B) Eighteen patients (May 2010-December 2012): alemtuzumab lot #84039D 20 mg/m2 and thymoglobulin 3-7 mg/kg.$

Conditioning regimen and inoculum. (A) Twenty-five patients (September 2008-October 2009): 8 Gy in a single fraction at a fast dose rate with lung shielding on day –10, thiotepa (4 mg/kg per day) on days –10 and −9, fludarabine (40 mg/m² per day) from days –10 to –6, and cyclophosphamide (35 mg/kg per day) on days –7 and –6. (B) Eighteen patients (May 2010-December 2012): alemtuzumab lot #84039D 20 mg/m² and thymoglobulin 3-7 mg/kg.

This Feature Is Available To Subscribers Only